AIM ImmunoTech Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
AIM NYSE American 2830 aimimmuno.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AIM ImmunoTech Inc.

AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - Mar 11th, 2025 12:45 pm
AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza - Feb 28th, 2025 1:45 pm
AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance - Feb 26th, 2025 6:20 pm
AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director - Feb 26th, 2025 1:30 pm
AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer - Feb 25th, 2025 1:30 pm
AIM ImmunoTech Releases Virtual Investor “What This Means Segment” - Feb 11th, 2025 1:45 pm
AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 - Feb 11th, 2025 1:30 pm
AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM’s Ampligen® and AstraZeneca’s FluMist® to address the recent avian influenza outbreaks - Feb 7th, 2025 1:50 pm
Erasmus Medical Center Safety Committee Grants Approval to Proceed with Phase 2 Study of Ampligen® and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer - Feb 5th, 2025 1:00 pm
AIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions - Jan 23rd, 2025 1:50 pm
AIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFS - Jan 22nd, 2025 1:30 pm
AIM ImmunoTech (AIM) Upgraded to Strong Buy: What Does It Mean for the Stock? - Jan 17th, 2025 5:00 pm
AIM ImmunoTech Highlights Key 2024 Achievements and Outlines Upcoming 2025-26 Value-Driving Milestones - Jan 15th, 2025 2:05 pm
AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards - Dec 17th, 2024 9:45 pm
AIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual Meeting - Dec 17th, 2024 8:10 pm
AIM ImmunoTech Reminds Shareholders to Vote "FOR" All Four Incumbent Board Members on the WHITE Universal Proxy Card - Dec 16th, 2024 1:00 pm
Kellner Group Denounces False Rumors About AIM Short Selling and Demands Immediate Accountability from Incumbent Board - Dec 14th, 2024 9:54 pm
UPDATE: Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card - Dec 13th, 2024 8:48 pm
AIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card "FOR" All Four Incumbent Board Members - Dec 12th, 2024 8:00 pm
AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue - Dec 12th, 2024 2:00 pm